Tinea Pedis (Athlete Foot) - Pipeline Review, H1 2017

  • ID: 4318752
  • Report
  • Region: Global
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Biolab Farmaceutica Ltda
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • MORE
Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape.

Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical, Discovery and Unknown stages are 1, 5, 2, 1 and 1 respectively.

Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Biolab Farmaceutica Ltda
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • MORE
  1. Introduction
  2. Tinea pedis (Athlete Foot) - Overview
  3. Tinea pedis (Athlete Foot) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Tinea pedis (Athlete Foot) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Tinea pedis (Athlete Foot) - Companies Involved in Therapeutics Development
  13. Astellas Pharma Inc
  14. Biolab Farmaceutica Ltda
  15. Blueberry Therapeutics Ltd
  16. Dermala Inc
  17. Helix BioMedix Inc
  18. Novan Inc
  19. Sol-Gel Technologies Ltd
  20. Viamet Pharmaceuticals Inc
  21. Tinea pedis (Athlete Foot) - Drug Profiles
  22. AS-2077715 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. dapaconazole - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. Drug for Athlete's Foot - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. E-06 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. HB-1275 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. nitric oxide - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. SB-208 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. terbinafine hydrochloride - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. terbinafine hydrochloride - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. VT-1161 - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. Tinea pedis (Athlete Foot) - Dormant Projects
  63. Tinea pedis (Athlete Foot) - Product Development Milestones
  64. Featured News & Press Releases
  65. Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
  66. Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
  67. Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
  68. Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
  69. Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
  70. Appendix
  71. Methodology
  72. Coverage
  73. Secondary Research
  74. Primary Research
  75. Expert Panel Validation
  76. Contact Us
  77. Disclaimer
List of Tables
  1. Number of Products under Development for Tinea pedis (Athlete Foot), H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Tinea pedis (Athlete Foot) - Pipeline by Astellas Pharma Inc, H1
  9. Tinea pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda, H1
  10. Tinea pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, H1
  11. Tinea pedis (Athlete Foot) - Pipeline by Dermala Inc, H1
  12. Tinea pedis (Athlete Foot) - Pipeline by Helix BioMedix Inc, H1
  13. Tinea pedis (Athlete Foot) - Pipeline by Novan Inc, H1
  14. Tinea pedis (Athlete Foot) - Pipeline by Sol-Gel Technologies Ltd, H1
  15. Tinea pedis (Athlete Foot) - Pipeline by Viamet Pharmaceuticals Inc, H1
  16. Tinea pedis (Athlete Foot) - Dormant Projects, H1
List of Figures
  1. Number of Products under Development for Tinea pedis (Athlete Foot), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Biolab Farmaceutica Ltda
  • Blueberry Therapeutics Ltd
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • Viamet Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll